Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

Employees

Sector

Biotechnology & Medical Research

Calendar

23/07 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
10/25/10	31.29 $	+2.93%	32,57,552
09/25/09	30.40 $	+0.70%	56,32,559
08/25/08	30.19 $	+9.74%	59,66,110
07/25/07	27.51 $	-2.41%	29,03,587
03/25/03	28.19 $	+1.70%	23,83,469

Delayed Quote Nasdaq, July 11, 2025 at 01:30 am IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

31.29USD

Average target price

90.26USD

Spread / Average Target

+188.47%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 01:30:00 11/07/2025 am IST			5-day change	1st Jan Change
31.29 ^USD	+2.93%		+11.00%	-22.24%

04/07	Viking Therapeutics Insider Sold Shares Worth $747,633, According to a Recent SEC Filing	MT
01/07	Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell Midcap Value Index	CI

Capitalization	341.42Cr 292.12Cr 272.2Cr 251.72Cr 467.24Cr 29TCr 520.19Cr 3.25TCr 1.24TCr 14TCr 1.28TCr 1.25TCr 50TCr	P/E ratio 2025 *	-16.2x	P/E ratio 2026 *	-12x
Enterprise value	267.07Cr 228.51Cr 212.92Cr 196.91Cr 365.49Cr 23TCr 406.91Cr 2.55TCr 972.3Cr 11TCr 1TCr 981Cr 39TCr	EV / Sales 2025 *	1,816x	EV / Sales 2026 *	436x
Free-Float	92.4%	Yield 2025 *	-	Yield 2026 *	-

Viking Therapeutics Insider Sold Shares Worth $747,633, According to a Recent SEC Filing	04/07	MT
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell Midcap Value Index	01/07	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell 3000 Value Index	01/07	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell 2500 Value Index	30/06	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell 1000 Value Index	30/06	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell Small Cap Comp Value Index	30/06	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell 3000E Value Index	30/06	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell 2500 Value Benchmark	30/06	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell Midcap Value Benchmark	30/06	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell 3000 Value Benchmark	30/06	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell 3000E Value Benchmark	30/06	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell Small Cap Comp Value Benchmark	30/06	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell 1000 Value Benchmark	30/06	CI

Cantor Fitzgerald Initiates Viking Therapeutics at Overweight With $104 Price Target	29/04	MT
Truist Securities Cuts Viking Therapeutics Price Target to $75 From $95, Maintains Buy Rating	25/04	MT
B. Riley Adjusts Price Target on Viking Therapeutics to $85 From $96, Maintains Buy Rating	24/04	MT
Oppenheimer Cuts Price Target on Viking Therapeutics to $100 From $164, Keeps Outperform Rating	23/04	MT
Goldman Sachs Initiates Viking Therapeutics With Neutral Rating, $30 Price Target	08/04	MT

Viking Therapeutics, Inc. Share Price

Equities

VKTX

US92686J1060

Biotechnology & Medical Research

Valuation: Viking Therapeutics, Inc.

Chart: Viking Therapeutics, Inc.

Latest news: Viking Therapeutics, Inc.

Last Transcript: Viking Therapeutics, Inc.

Analysts' recommendations: Viking Therapeutics, Inc.

Press Releases: Viking Therapeutics, Inc.

News in other languages: Viking Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Viking Therapeutics, Inc.

ETFs: Viking Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Viking Therapeutics : July 2025 Corporate Presentation	03/07	PU
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735	25/06	PR
Viking Therapeutics : June 2025 Corporate Presentation	14/06	PU
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025	17/04	PR
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity	26/03	PR

Píldora adelgazante de Eli Lilly funciona tan bien como Ozempic en un ensayo	17/04
MÄRKTE USA/Fester - Hoffnung auf weitere Zollausnahmen stützt Kurse	15/04
Pfizer met fin au développement de sa pilule amaigrissante danuglipron	14/04
AKTIEN IM FOKUS 3: Kursrutsch bei Novo Nordisk und Gerresheimer - Lilly steigt	20/12
AKTIEN IM FOKUS 2: Studie wirft Novo Nordisk weit zurück - Gerresheimer schwach	20/12

1 day	+2.93%
1 week	+11.00%
Current month	+18.08%
1 month	+7.38%
3 months	+45.40%
6 months	-20.40%
Current year	-22.24%

1 week	27.1	31.57
1 month	23.8	31.57
Current year	18.92	43.55
1 year	18.92	81.73
3 years	2.53	99.41
5 years	2.02	99.41
10 years	0.88	99.41

Manager	Title	Age	Since
Brian Lian CEO	Chief Executive Officer	59	24/09/2012
Gregory Zante DFI	Director of Finance/CFO	54	04/01/2021
Marianne Mancini COO	Chief Operating Officer	60	04/01/2021

Director	Title	Age	Since
Lawson Macartney CHM	Chairman	67	01/05/2015
Brian Lian CHM	Chairman	59	24/09/2012
Matthew Foehr BRD	Director/Board Member	52	01/05/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
VIKING THERAPEUTICS, INC.	+2.93%	+11.00%	-46.04%	+817.60%	341.42Cr
ARGENX SE	+4.39%	+3.76%	+16.68%	+39.32%	3.33TCr
WUXI APPTEC CO., LTD.	+0.63%	-0.09%	+88.24%	-36.35%	2.78TCr
BIONTECH SE	+1.91%	+3.56%	+40.12%	-33.04%	2.75TCr
SUMMIT THERAPEUTICS INC.	+4.61%	+5.42%	+212.18%	+2,437.25%	1.84TCr
INSMED INCORPORATED	+0.20%	-1.17%	+32.23%	+289.76%	1.83TCr
WUXI BIOLOGICS (CAYMAN) INC.	-0.77%	+0.19%	+137.08%	-67.88%	1.34TCr
GENMAB A/S	+1.68%	+7.60%	-20.92%	-44.09%	1.32TCr
AKESO, INC.	-1.37%	+16.70%	+190.35%	+341.14%	1.26TCr
EXELIXIS, INC.	+2.50%	-2.12%	+104.85%	+105.22%	1.2TCr
Average	+1.18%	+4.50%	+75.48%	+384.89%	1.8TCr
Weighted average by Cap.	+1.39%	+3.10%	+75.89%	+312.97%

	2025 *	2026 *
Net sales	14.71L 12.58L 11.72L 10.84L 20.13L 13Cr 22.41L 1.4Cr 53.54L 5.89Cr 55.15L 54.02L 22Cr	64.49L 55.18L 51.41L 47.55L 88.25L 55Cr 98.25L 6.15Cr 2.35Cr 26Cr 2.42Cr 2.37Cr 94Cr
Net income	-22Cr -19Cr -17Cr -16Cr -30Cr -1.87TCr -33Cr -208.38Cr -80Cr -875.81Cr -82Cr -80Cr -3.2TCr	-30Cr -26Cr -24Cr -22Cr -41Cr -2.59TCr -46Cr -287.92Cr -109.96Cr -1.21TCr -113.27Cr -110.94Cr -4.42TCr
Net Debt	-74Cr -64Cr -59Cr -55Cr -101.75Cr -6.38TCr -113.28Cr -708.76Cr -270.68Cr -2.98TCr -278.82Cr -273.1Cr -11TCr	-60Cr -51Cr -48Cr -44Cr -82Cr -5.15TCr -92Cr -572.63Cr -218.69Cr -2.41TCr -225.27Cr -220.65Cr -8.8TCr